1. Scrip
  2. >>Rare Diseases

AstraZeneca And Ionis ATTR Ambitions Boosted

Efficacy of Eplontersen Maintained For 66 Weeks

 
• By Kevin Grogan

The companies are hoping that new data on recently-filed eplontersen will boost the drug's chances of challenging Alnylam’s Amvuttra and Onpattro.

DATA_Puzzle Piece_186976547_1200.jpg
More data added in support of eplontersen • Source: Shutterstock

A few weeks after filing eplontersen with regulators in the US, AstraZeneca PLC and Ionis Pharmaceuticals, Inc. have presented positive long-term data for the transthyretin amyloidosis (ATTR) therapy.

At the beginning of March, the companies filed eplontersen with the US Food and Drug Administration for patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) on the back of 35-week interim...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Rare Diseases

InflaRx Stock Sinks As Vilobelimab Fails Phase III Skin Trial

 
• By Kevin Grogan

A study of the German biotech's intravenous complement factor C5a antibody for pyoderma gangrenosum was stopped for futility.

Sweden’s Hansa Slims Down Ahead of Key Readouts

 
• By Kevin Grogan

New CEO Renée Aguiar-Lucander is marking her mark.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Lundbeck Lifted By Leap In Migraine Therapy Sales

 
• By Kevin Grogan

Vyepti revenues rise by nearly 70% in the first quarter.

More from Scrip

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

 
• By Joseph Haas

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

GlycoEra’s Series B Cash Will Fund Efforts To Take On FcRn Inhibitor Class

 
• By Joseph Haas

GlycoEra unveiled a $130m series B financing, saying the proceeds would enable it to take its first clinical candidate through proof-of-concept in autoimmune diseases.